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Prostanoids exert physiological effects on ureteral contractility
that may lead to pressure changes and pain during
obstruction. In the present study, we examined whether (1)
obstruction changes the expression of the two cyclooxygenase
(COX) isoforms, COX-1 and COX-2 in human and rat ureters and
(2) administration of a selective COX-2 inhibitor influences the
pelvic pressure change after experimental ureteral obstruction.
Rats were subjected to bilateral ureter obstruction. Ureters
were removed and dissected into a proximal dilated and distal
non-dilated segment. RNA and protein were extracted and
analyzed for cyclooxygenase expression by quantitative
polymerase chain reaction and Western blotting. Human ureter
samples were obtained from patients undergoing radical
nephrectomy. Rat and human ureteral samples were processed
for immunohistochemistry. COX-1, but not COX-2 mRNA, was
readily detected in the normal rat ureter. COX-2 mRNA and
protein expression was increased in the proximal dilated ureter
compared to distal non-dilated ureter. This increased COX-2
expression was associated with increased urinary
prostaglandin E2 (PGE2) excretion after release of obstruction.
Immunohistochemistry showed increased COX-2 labeling in
surface epithelium and smooth muscle layers in both rat and
human obstructed ureters compared to control ureters.
Furthermore, contractile PGE2-EP1 and thromboxane TP
receptors were expressed in ureteral smooth muscle. Systemic
treatment with the COX-2 selective inhibitor parecoxib (5 mg/
kg/day) attenuated the pelvic pressure increase during
obstruction. In summary, COX-2 expression is significantly
increased in the ureteral wall in response to obstruction in the
rat and human ureter and COX-2 activity contributes to
increased pelvic pressure after obstruction.
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Inhibitors of cyclooxygenase (COX) activity and prostanoid
synthesis are widely used to decrease contractility, pressure,
and pain associated with ureteral obstruction.1–4 COX is the
major rate-limiting enzyme in the cascade leading to
synthesis of prostanoids from arachidonic acid. Two isoforms
of COX have been identified, namely COX-1 and COX-2. The
COX-1 isoform is believed to be constitutively expressed in
most cells and involved in the maintenance of various
physiological functions,5 whereas COX-2 is produced in
response to injurious stimuli such as inflammation. COX-2
expression is elevated in the renal medulla in response to
ureteral obstruction.6–8 It is not known whether the ureteric
wall contributes to prostaglandin production in conditions
with ureteral obstruction, but previous studies indicate that
COX-2 mRNA and protein levels are upregulated in
chronically obstructed human ureters.6,9 In studies using
isolated rings from the pig ureter, treatment with a selective
COX-2 inhibitor reduced TNFa-induced contractility.4 In the
rat bladder, complete outlet obstruction induces COX-2
expression dramatically in the smooth muscle cells, whereas
COX-1 expression remains unchanged.8 In the present study,
we hypothesized that increased local stretch stimulates COX-2
expression in the ureteric wall and leads to subsequent
increase of contractility and pressure. This concept has not
been tested in vivo and the cellular localization of COX-2
protein in human and animal ureters is not clear. We used an
approach where the proximal dilated ureter was compared to
the distal part of the same ureter after experimental
occlusion. Thus, the degree of stretch in each part would
differ markedly, whereas systemic influences (hormones,
nervous activity etc.) are equal.
Prostaglandin E2 (PGE2) is abundantly produced in
kidney by PGE2-synthase (PGES), but it is not known
whether PGES is expressed and regulated in the ureter during
obstruction. Prostanoids interact with a family of distinct
G-protein-coupled receptors designated prostaglandin E2
(EP), prostaglandin F2a (FP), prostaglandin I2 (IP), throm-
boxane (TP), and prostaglandin D2 (DP).
10 Activation of the
FP, TP, and EP1 receptors lead to calcium mobilization and
contraction of smooth muscle cells.11 In contrast, stimulation
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of EP2, EP4, DP, and IP receptors relax smooth muscle cells
through formation of cyclic adenosine 30,50 monophosphate,
whereas activation of the EP3 inhibits the ability to generate
cyclic adenosine 30,50 monophosphate and results in
constriction.11 Previously, it was demonstrated that prosta-
glandin-F2a and tromboxane-A2 contract the smooth muscle
cells of the urinary tract.12 PGE2 increases contractility in the
pig ureter rings through activation of the EP3 receptor.13
However, under normal physiologic conditions in ureters,
PGE2 has a predominant relaxing effect.
14 Based on these
observations, it appears that PG receptors are present in the
ureter, but there is currently no data available on the subset
of receptors expressed in the ureter and their cellular
association.
The aims of the present study are therefore to examine
whether (1) ureteral obstruction changes the expression of
COX-1, COX-2, and PGES in the rat and human ureter and
(2) administration of a selective COX-2 inhibitor in vivo
influences the pelvic pressure after experimental ureter
obstruction in rats. Moreover, the expression and distribu-
tion of downstream prostanoid receptors located to the
ureteric wall in rats were examined.
RESULTS
Increased COX-2 expression in the ureteric wall in response
to ureteral obstruction
Reverse transcriptase-polymerase chain reaction (RT-PCR)
performed with RNA from control ureters yielded no
amplification products for COX-2 (Figure 1a), whereas
COX-1 products were readily detectable (Figure 2a). After
24 h of obstruction, the abundance of COX-2 mRNA
normalized for b-actin was increased 18-fold in the proximal
dilated part of ureter compared to the distal part of the same
ureter (Figure 1b). COX-1 mRNA level was also significantly
elevated 1.5-fold in the proximal part of the obstructed ureter
compared to the distal part of the ureter (Figure 2b). After
3 h, the abundance of COX-2 protein normalized for b-actin
was increased in the proximal obstructed ureter compared to
the distal part of the same ureter (arbitrary units: 3.070.4 vs
0.370.2, Po0.001, Figure 1c). Western blot analysis showed
that the COX-2 protein is composed of a 72 and a 74 kDa
form, which is caused by a variability in the N-glycosylation
of Asn580.15 In sham-operated control rats, the expression of
COX-2 was not above the detection limit (Figure 1c). This
was confirmed by immunohistochemical analysis where
COX-2 showed very weak labeling of the urothelium and
no labeling of the smooth muscle or adventitia in the ureter
of sham-operated rats (Figure 1d). In the obstructed ureter,
COX-2 immunoreactivity was detected in the smooth muscle
cells and a markedly increased labeling was seen in the
urothelium (Figure 1f and g). Incubation of COX-2 antibody
with immunizing peptide abolished all labeling (Figure 1e).
Immunoblotting showed no significant difference in COX-1
protein normalized for b-actin between the proximal and
distal parts of the obstructed ureter (arbitary units: 1.270.2
vs 0.970.3, Figure 2c). COX-1 immunoreactivity was
restricted to the urothelium layers and was particularly
associated with basal cells (Figure 2d). Omission of primary
COX-1 antibody prevented the labeling (Figure 2e). Im-
munohistochemical analysis for COX-1 was also performed
on obstructed ureters, but there was no change in the labeling
compared to control ureters (data not shown).
Immunohistochemical localization of COX-2 in human
obstructed ureters
Sections of non-obstructed human ureters displayed distinct,
but very limited labeling for COX-2. Immunoreactivity was
associated with few cells in the basal layer of the urothelium
and this was scattered along the perimeter. No labeling was
observed in media smooth muscle or adventitia (Figure 3a, d,
and g). Sections of chronically obstructed ureters were
markedly thickened compared to normal ureters (Figure 3b
vs a). This was caused by hypertrophy of media smooth
muscle, which was arranged in large, clearly discernible
bundles not present in normal ureters (Figure 3b, f, and i).
Obstructed ureters exhibited strong immunohistochemical
labeling for COX-2 associated with all layers of the
urothelium (Figure 3b and e) and smooth muscle layer
(Figure 3c and f). Notably, blood vessels in the wall of the
obstructed human ureters displayed hypertrophy, and both
media and endothelium were COX-2 positive (Figure 3c).
Immunofluorescence labeling confirmed the immunohisto-
chemical data (Figure 3g–i).
Increased level of downstream targets for COX products
in response to ureteral obstruction
The expression of PGES protein normalized for b-actin was
significantly increased in the proximal dilated part of the
occluded ureters compared to the distal part of the same
ureters (arbitary units: 1.470.1 vs 0.670.04, Po0.05, Figure
4a). In sham ureters, there was a marked labeling for PGES in
the urothelium layers and more faintly in smooth muscle
cells (Figure 4b). Obstruction did not cause any changes in
the intensity of the labeling in PGES (Figure 4b and c).
Sections from non-obstructed human ureter specimens
displayed very faint immunofluorescense signal for PGES in
basal epithelial cells (Figure 4d). In the obstructed human
ureters, the PGES signal was more intense and more widely
distributed in the majority of luminal epithelial cells and was
not observed in media smooth muscle comparable to the
obstructed ureters from the rat (Figure 4e). Release of
ureteral obstruction was associated with a significant increase
in urinary PGE2 excretion (2.570.4 vs 1.970.3 ng/min/day,
Po0.05, Figure 4f).
Effect of a COX-2 selective antagonist on pelvic pressure
before and during ureteral obstruction
The baseline pelvic pressure was significantly elevated by
administration of a COX-2 inhibitor, parecoxib, compared to
vehicle-treated control rats (1971.4 vs 1372.5 mm Hg,
Po0.05, Figure 5b). After onset of obstruction, the pelvic
pressure increased rapidly in both groups. After 1 h, the
pressure stabilized at 6273.5 mm Hg in the vehicle-treated
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rats, whereas it was significantly lower in the COX-2-
inhibitor-treated rats (5172.5 mm Hg) (Figure 5c). After
release of obstruction, the pelvic pressure decreased to the
levels observed before obstruction. Thus, the pressure
increase (Dpressure) was significantly lower in the COX-2-
inhibitor-treated rats compared with controls (3272.7 vs
4973.5 mm Hg, n¼ 6, Po0.05, Figure 5d).
Figure 5b displays upper urinary tract peristalsis before,
during, and after release of obstruction in vehicle- and
parecoxib-treated rats.
Identification of prostaglandin receptors in rat ureter
Expression of PGE2-EP1, -EP2, and -EP4 receptors and TP
were observed in control ureters. Up to 35 cycles of
amplification yielded no or faint cDNA products for DP,
EP3, IP, and FP receptors (Figure 6). Cytoplasmic b-actin was
equally amplified from the three preparations of ureters
(Figure 6).
Next, we investigated whether EP2 and TP receptors
are changed by obstruction. Semiquantitive immunoblot-
ting showed that the abundance of EP2 receptor protein
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Figure 1 | Expression of COX-2 mRNA and protein in control and obstructed ureters. (a) Representative RT-PCR for COX-2. RNA was
isolated from control ureter, reverse-transcribed with and without reverse transcriptase, and subjected to amplification for 32 cycles. No COX-2
mRNA expression was detected in the control ureters. Positive controls were from rat kidney. Size marker is X174DNA/HaeIII fragments.
(b) Representative Q-PCR for COX-2 and b-actin. Obstructed ureters were dissected in two halves, a proximal and distal part and RNA was
isolated from each part. Q-PCR was performed using 50 ng cDNA. Each column represents the mean7s.e.m. of eight determinations. Units are
1 1013 g; *Po0.05 proximal part of the ureter compared with the distal part. (c) Immunoblot was reacted with anti-COX-2 antibody and
revealed in two discernible bands of 72 and 74 kDa. b-Actin was used as an internal standard. Densitometric analyses of all the samples from
sham-operated and the proximal and distal part of the obstructed ureters revealed that there was a marked increase of COX-2 protein level in
the proximal obstructed part compared to the distal part of the ureters and ureters from sham-operated rats. Each column represents the
mean7s.e.m. of five determinations; *Po0.05 proximal part of the ureter compared with the distal part. $Po0.05 proximal part of the ureter
compared with ureter from sham rats. (d–g) Immunohistochemistry for COX-2 of ureters from (d) control rats and (f–g) rats with ureteral
obstruction. (d) In control ureters, COX-2 showed very distinct labeling of the urothelium and no labeling of the smooth muscle or adventitia.
(f–g) In the obstructed ureters, COX-2 immunoreactivity was detected in the smooth muscle cells and the urothelium and the labeling was
much stronger compared to controls. (e) Incubation of COX-2 with peptide used to raise the antibody completely prevented labeling.
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normalized to b-actin was not significantly different in the
proximal obstructed part compared to the distal part of the
ureter (Figure 7a). The TP receptor antibody detects the TP
receptor at 55 and 64 kDa. We performed densitometry of
each band individually and observed that only the smaller
one normalized to b-actin was increased in the proximal
obstructed part of the ureter compared to the distal part of
the ureter (arbitary units: 1.370.1 vs 0.870.1, Po0.05,
Figure 7d). Immunohistochemical labeling confirmed the
presence of EP2 (Figure 7b) and TP (Figure 7e) receptors in
smooth muscle and urothelium layers of control ureters.
Incubation of the sections without primary antibody
completely prevented labeling (Figure 7c and f).
DISCUSSION
The present study showed that experimental occlusion of the
rat ureter leads to a significant upregulation of COX-2 at
both mRNA and protein levels in the proximal dilated ureter
segment compared to the distal part of the same ureter. COX-
1 protein level and immunolabeling for COX-1 did not
change in the two ureteral segments after obstruction. The
expression of PGES was enhanced in the proximal dilated
part of the ureter compared to the distal ureter and urinary
excretion of PGE2 increased after release of obstruction. In
both rat and human obstructed ureters, COX-2 immunor-
eactivity was detected in the surface epithelium (‘urothe-
lium’) and smooth muscle. Pretreatment with a COX-2
inhibitor increased baseline pelvic pressure but attenuated
the pelvic pressure increase in response to obstruction
compared to obstructed vehicle-treated control rats. Further-
more, the expression of ‘dilatory’ PGE2-EP2 and EP4
receptors and ‘constricting’ prostanoid receptors (TP and
EP1) was demonstrated in control ureters. At the protein
level, we observed localization of EP2 and TP receptors in
control ureters.
Increased COX-2 levels in obstructed ureters
Our findings are consistent with previous reports that
demonstrated elevated COX-2 mRNA and protein levels in
human obstructed ureters.6,9 Compared to normal ureters,
we observed a strong COX-2 labeling in the urothelium as
well as smooth muscle of the obstructed ureters in both rats
and humans. These results are supported by the findings of
Jerde et al.9 who separated porcine ureteral segments into
urothelium and smooth muscle layers and demonstrated
COX-2 induction in both the urothelium and smooth muscle
of the obstructed ureters. Importantly, in the present study,
the obstructed proximal part of the ureters were analyzed in
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Figure 2 | Expression of COX-1 mRNA and protein in control and obstructed ureters. (a) Representative RT-PCR for COX-1. RNA was
isolated from control ureter, reverse-transcribed with and without reverse transcriptase, and subjected to amplification for 32 cycles. COX-1
mRNA expression was detected in the control ureters. Controls were from rat kidney. Size marker is X174DNA/HaeIII fragments.
(b) Representative Q-PCR for COX-1 and b-actin. Obstructed ureters were dissected into two halves, a proximal and distal part and RNA was
isolated from each part. Q-PCR was performed using 50 ng cDNA. Each column represents the mean7s.e.m. of eight determinations. Units are
1 1013 g; *Po0.05 proximal part of the ureter compared with the distal part. (c) Immunoblot was reacted with anti-COX-1 antibody and
revealed a singleB71 kDa band. b-Actin was used as an internal standard. Densitometric analyses of all the samples from sham-operated and
the proximal obstructed and distal part of the ureters revealed that there was no change in the COX-1 protein level between the proximal
obstructed and distal part of the ureters. The COX-1 protein expression in the ureters from sham-operated rats did not differ from the
obstructed rats. Each column represents the mean7s.e.m. of five determinations. (d–e) Immunohistochemistry for COX-1 of ureter from
(d) control rats showed labeling of the urothelium. (d) Omission of primary COX-1 antibodies completely prevented labeling.
Kidney International (2006) 70, 872–881 875
R Nørregaard et al.: COX-2 upregulation in obstructed rat and human ureter o r i g i n a l a r t i c l e
comparison to the distal unobstructed part of the ureters.
As the distal ureter was exposed to the same systemic
nervous and humoral signals as the proximal part, the
present results suggest that local factors are responsible for
upregulation of COX-2. We recorded a sharp rise in
intrapelvic pressure after occlusion. This leads to mechanical
stretch of the pelvic wall and ureter. It is therefore likely that
local wall stress is the dominant factor responsible for the
difference in COX-2 expression between different segments of
the same ureter. This view is supported by the findings of
Park et al.16 who showed that mechanical stretch of the
bladder induces COX-2 expression, indicating that COX-2
is involved in the pathophysiology of bladder outlet
obstruction.
PGE synthase was constitutively expressed in both human
and rat ureters and was associated with the urothelium.
Recent in vitro experiments on acutely obstructed ureters
showed that low concentrations of PGE2 decreased ureteral
contractility in a dose-dependent fashion.3 Consistent with a
tonic relaxing effect of COX-2 activity, we found that COX-2
inhibition increased baseline pelvic pressure despite very low
levels of COX-2 protein in the ureter. In sharp contrast,
Lowry et al.14 demonstrated that PGE2 increased the
contractility of chronically obstructed human ureter seg-
ments in vitro. Moreover, we found that obstruction
enhanced PGES abundance and PGE2 release.
Systemic administration of the selective COX-2 inhibitor,
parecoxib, significantly attenuated the increased pelvic
pressure during obstruction. Thus, our data support the
notion that obstruction in vivo leads to COX-2-mediated
increased PGE2 which contributes to the pelvic pressure
increase. Previously, it was demonstrated that ureteral
obstruction is followed by increased intrapelvic pres-
sure.2,17,18 This pressure increase can be attenuated by
nonspecific blockade of the prostaglandin system, which
reduces the glomerular filtration pressure by an increase in
the afferent arteriole resistance.2,19 Furthermore, studies have
shown that administration of PGE2 and prostaglandin-F2a to
isolated ureteric smooth muscle increase the contractile
activity and that this enhanced contractile response can be
attenuated by administration of nonspecific COX inhibi-
tors.20,21 Importantly, recent in vitro studies have demons-
trated that a selective COX-2 inhibitor (NS-398) inhibits
ureteral contractility stimulated by inflammatory mediators,
both in isolated porcine and human ureteral ring prepara-
tions.4 It might therefore be speculated that selective COX-2
inhibition in our in vivo experiments reduces pelvic pressure
through a direct effect on smooth muscle activity in the renal
pelvis and upper urinary tract. However, we cannot rule out
that a decreased glomerular filtration rate also contributes to
the inhibitor-mediated fall in pelvic pressure. Further studies
are needed to discriminate and quantitate the importance of
Control Obstructed ureter
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Figure 3 | Immunohistochemical labeling of human ureter for COX-2. (a, d, g) Non-obstructed ureters and (b, c, e, f, h, i) obstructed ureters.
(a, d, g) The control ureters on the left panel showed COX-2-positive cells in the urothelium but no labeling of COX-2 in the smooth muscle
cells. In the human obstructed ureter, intensive COX-2 labeling was observed (b, e, h) in the urothelium and (c, f, i) smooth muscle cells.
Bars¼ 200 mm in (a and b) and 50mm in (c–i).
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renal hemodynamic and pelvic viscoelastic property changes
by COX-2 inhibition in response to obstruction of the ureter.
Altogether, our findings suggest that enhanced COX-2-
mediated PGE2 production and release during obstruction
enhances contractility and aggravates the pelvic pressure
increase. However, it should be stressed that the use of a
COX-2 inhibitor may precipitate acute renal failure in
addition to relieving pain during this condition.22
Previously, it was demonstrated that there exists species-
specific differences in the relative importance of COX-1 and
COX-2 in maintaining contractility of the upper urinary tract
function.23 We did not address specifically the role of COX-1,
but the stable and comparatively low levels of COX-1
expression during obstruction suggest a less prominent role
of COX-1 in the pathophysiology of obstructive pressure
increase.
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Figure 4 | Expression of PGES protein in control and obstructed
ureters. (a) Immunoblot was reacted with anti-PGES antibody and
revealed a single B16 kDa band. b-Actin was used as an internal
standard. Densitometric analyses of all the samples from sham-
operated and the proximal obstructed and distal part of the ureters
revealed an increase of PGES protein level in the proximal obstructed
part compared to the distal part and to sham-operated rats. Each
column represents the mean7s.e.m. of five determinations; *Po0.05
proximal part of the ureter compared with the distal part. (b–c)
Immunohistochemical labeling for PGES of ureter from (b) control
rats and (c) proximal dilated ureters showed labeling of the
urothelium and smooth muscle cells. There was no difference in the
labeling pattern between ureters from control and obstructed rats.
(d–e) Immunohistochemistry for PGES of ureter from (d) human
control and (e) obstructed ureters. In the human obstructed ureter,
marked PGES labeling was observed in (e) the urothelium, whereas
the control ureter showed very weak labeling of PGES in (d) the
urothelium. Bars¼ 50mm in (d and e). (f) Effect of obstruction on
urinary PGE2 excretion. BUO was induced for 24 h followed by 24 h
release period and urinary PGE2 was measured. Each column
represents the mean7s.e.m. of six determinations. *Po0.05 BUO
compared with sham rats.
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Figure 5 | Pelvic pressure in vehicle and parecoxib-treated rats.
(a) Transparenchymal placement of the catheter and access line in rat
model with ureteral obstruction. (b) Typical example of original trace
showing peristaltic pressure waves before, during, and after release
of obstruction in both vehicle- and parecoxib-treated rats. Before
obstruction solitary waves characterized by a uniform shape were
observed. During the contraction maximal pressure amplitude of
1–2 mm Hg is attained. The pressure wave frequency in the pelvis is
around 10–15/min. There was no difference in the configuration of
the peristaltic pressure waves between the vehicle- and parecoxib-
treated rats before obstruction. During obstruction, the pressure
waves showed decreasing amplitude to nearly 0.5–1 mm Hg and
increase in the frequency of peristalsis which was not possible to
quantify. After release of obstruction, isolated waves of very uniform
appearance with an amplitude of 1–2 mm Hg were observed, but
with a lower pressure wave frequency, which was approximately 5–8/
min. There was no variation among the control- and parecoxib-
treated rats. The pelvic peristaltic waves could at the baseline level
clearly be distinguished from respiratory and pulsative oscillations,
which had a shorter duration and amplitude and much higher
frequency. (c) Baseline renal pelvic pressure differed significantly
between the vehicle- and parecoxib-treated groups. Pelvic pressure
was significantly lower in the parecoxib-treated rats after 30 and
60 min obstruction compared with vehicle-treated rats. (d) The
pressure increase (Dpressure) was significantly lower with COX-2
inhibition compared to vehicle-treated obstructed rats.
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Expression of prostanoid receptors in the ureter
Different classes of prostanoid receptors were present in the
ureter. The ‘dilatory’ receptors EP2 and EP4 could be
involved in the relaxing effect of basal COX-2 activity that
was revealed by COX-2 inhibition. On the other hand, EP1
and TP receptors are excitatory for smooth muscle and are
potential candidates for the contractile effect of COX-2
activity after obstruction. TP receptor protein abundance was
increased in the proximal obstructed ureter compared to the
distal part of the ureter. TP immunoreactive protein was
associated with the smooth muscle in the ureter wall and
blood vessels. Marked vascular stasis with vessel hypertrophy
was observed in the human obstructed ureters. Thus, local
thromboxane formation may potentially be increased in
obstructed ureters. Consistent with this, functional studies
have demonstrated that thromboxane contracts smooth
muscle cells in ureteral obstruction, supporting the func-
tional presence of tromboxane-A2 sensitivity at this site.
12 At
high concentrations, PGE2 may also function as a TP
agonist.24 It appears attractive to further characterize the
role for TP activation in the pressure increase in response to
obstruction. Thus, pharmacologic use of TP antagonists
could be a potential option for the treatment of obstruction.
We did not detect EP3 expression in rat ureters, but a recent
study demonstrated that the EP3 receptor is involved in
porcine ureteral contractility.13 An increased PGE2-mediated
contractility was observed in obstructed ureters that were
reversed by pertussis toxin. Moreover, selective activation of
the EP3 receptor with sulprostone, an EP3 agonist, increased
contraction of the obstructed ureter segments.13 Thus,
species differences could explain this difference.
MATERIALS AND METHODS
Experimental animals
The animal protocols were approved by the board at the Institute of
Clinical Medicine, University of Aarhus according to the licenses for
use of experimental animals issued by the Danish Ministry of Justice.
Studies were performed in male Munich-Wistar rats initially weighing
220 g (Møllegaard Breeding Centre, Eiby, Denmark). Rats were
anesthetized with isoflurane (Abbott Scandinavia AB, Solna, Sweden).
Through a midline abdominal incision, both ureters were exposed
and then occluded with a 5-0 silk ligature in the middle. Rats were
allocated to the protocols indicated below. Age- and time-matched,
sham-operated controls were observed in parallel with each bilateral
ureteral obstruction (BUO) group in the following protocols.
Protocol 1: (1) BUO was induced for 24 h (n¼ 8). Both ureters
were removed and severed at the site of occlusion in a proximal and
distal part. Proximal and distal segments and sham ureters were
analyzed by quantitative-PCR (Q-PCR) (n¼ 8 and 5, respectively).
Ureters were fixed for immunocytochemistry (n¼ 5).
Protocol 2: (1) BUO was induced for 3 h (n¼ 5). Both ureters
were removed and severed at the site of occlusion in a proximal and
distal part. The ureters were prepared for immunoblotting (n¼ 5).
Sham-operated controls were prepared in parallel and the ureters
were prepared for immunoblotting (n¼ 5).
Human tissue
All patients who donated tissue had given informed written consent
to participate. The study was performed in accordance with the
Declaration of Helsinki Principles and approved by the local review
board (‘Ethical Committee’) (Number 20010035). Tissue was
obtained from patients with renal cancer at the time of radical
nephrectomy. None of the patients had received chemo- or radiation
therapy before nephrectomy. Nephrectomy specimens were rapidly
transferred to the Institute of Pathology at Odense University
Hospital. Pieces (5–10 mm) of the proximal ureter from six different
patients (clear cell and papillary renal cancer) were excised by a
pathologist and fixed in 4% paraformaldehyde for 16 h and
embedded in paraffin. Two ureters displayed macroscopic dilation
and four appeared normal at macroscopic examination.
Isolation of RNA and PCR
Total RNA was isolated from rat ureters with the RNeasy mini kit.
The two proximal and distal ureteral segments were pooled from
one rat with obstruction and both ureters were pooled from one
control rat. RT-PCR was performed with the primer sets listed in
Table 1. Primers for COX-1, COX-225, and beta-actin26 were as
described previously. For Q-PCR, 50 ng cDNA in duplicate was used
as template and mixed with the respective primers: COX-1,25 COX-2
(Table 1) and beta-actin.26 Q-PCR was carried out using iQ-SYBR
Green Supermix (Biorad Life Science, Herlev, Denmark) and the
mixture was run on an iQ-Thermocycler (Biorad Life Science).
Negative controls with no cDNA and positive controls with kidney
cDNA were run in each plate.
Electrophoresis and immunoblotting
Protein was isolated and quantitated as described.7 Samples were
run on 9 and 12% polyacrylamide gels (Bio-Rad Protean II). For
each gel, an identical gel was run in parallel and subjected to
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Figure 6 | Prostanoid receptor expression in ureter from control
rats using RT-PCR. RNA was isolated from three separate prepara-
tions of control ureters, reverse-transcribed with and without reverse
transcriptase, and subjected to amplification by PCR for 32–33 cycles.
PGE2-EP1, EP2, and EP4 receptor and TP transcripts were detected in
the control ureters only in the presence of reverse transcriptase (þ ).
At similar cycle numbers, very faint or no amplification products were
detected for DP, EP3, IP, and FP. Positive controls were 50 ng cDNA
from rat kidney (EP1–EP4), cerebellum (DP), spleen (IP, TP), and heart
(FP). Rat b-actin was equally amplified from the three ureter
preparations. ‘’ indicates absence of reverse transcriptase in the
reactions. Size marker is X174DNA/HaeIII fragments.
878 Kidney International (2006) 70, 872–881
o r i g i n a l a r t i c l e R Nørregaard et al.: COX-2 upregulation in obstructed rat and human ureter
Coomassie staining. The Coomassie-stained gel was used to
ascertain identical loading or to allow for correction for minor
variations in loading after scanning and densitometry of major
bands (Figure 8). The other gel was subjected to blotting. Blotting
was performed as described.7
Immunohistochemistry
For optimal labeling of the paraffin-embedded tissue, antigen
recovery was routinely performed by microwaving for 20 min in
DAKO (Glostrup, Denmark) citrate buffer pH 6.0. For EP2 labeling,
tissue was boiled in citrate buffer in a pressure cooker for 5 min.
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Figure 7 | Expression of EP2 and TP receptor protein in control and obstructed ureters. (a) Immunoblot is reacted with anti-EP2 antibody
and revealed a singleB52 kDa band. b-Actin was used as an internal standard. Densitometric analyses of all the samples from sham-operated
and the proximal obstructed and distal part of the ureters revealed that there was no change in the EP2 protein level between the proximal
obstructed and distal part of the ureters. The EP2 protein expression in ureters from sham-operated rats was not different from the obstructed
rats. Each column represents the mean7s.e.m. of five determinations. (b–c) Immunohistochemistry for EP2 of ureter from control rats
(b) showed labeling of the urothelium. Omission of primary EP2 antibodies completely prevented labeling (c). (d) Immunoblot is reacted with
anti-TP antibody and revealed two bands atB55 and 64 kDa. b-Actin was used as an internal standard. Densitometric analyses were made of
each band of all the samples from sham-operated and the proximal obstructed and distal part of the ureters. There was no difference in the
64 kDa receptor protein expression; however, the 55 kDa TP protein level was increased in the proximal obstructed part compared to the
distal part of the ureters. The TP protein expression in ureters from sham-operated rats was not different from the proximal obstructed ureters.
Each column represents the mean7s.e.m. of five determinations *Po0.05 proximal part of the ureter compared with the distal part.
(e–f) Immunohistochemical staining for TP in ureter from (e) control rat showed labeling of the urothelium and smooth muscle cells.
(f) Omission of primary antibody completely prevented labeling.
Table 1 | Primer sequences used for RT-PCR and Q-PCR
Sense Anti-sense Acc. No Molecular size and localization in cDNA
rEP1 GTC GTG GAA CCA GAT CCT GCT ACG CAG TGA ACT GGC NM_013100 160, 1613–1772
rEP2 TTC GGA GCA AAA GAA GCC GAG CGC ATT AGT CTC AGG U94708 301, 725–1025,
rEP3 GCT GTC TGT GCT CGC CTT CCA TAA GCT GGA TAG NM_012704 311, 562–872,
rEP4 GGA AGA CTG TGC TCA GTA GAA GCA AAT TCT TGC CTC U94709 240, 1007–1246
rDP TCA GCG ACA ATG GGT GGT GT AAG TCG GTG ACT GTC AAG Af120101 164, 52–215
rFP TCA TCG CCA ACA CGA CTT AGA AGT CTG TGA TCA CCA XS74898 189, 47–235
rIP TCT TCC AAC GCC TCA AGT ACA GCA GTC AAT GGT GCC AC D28966 193, 1062–1254
rTP TCA GCT CGT AGG CAT CAT CGT AGG TAG ATG AGC AGT D21158 150, 1019–1168
rCOX-2** CGG GAT CCG AAA TGG CTG ATG GTG GCT GTC TTG GTA S67722 323, 1538–1860
COX, cyclooxygenase; EP, prostaglandin E2; DP, prostaglandin D2; FP, prostaglandin F2; IP, prostaglandin I2; Q-PCR, quantitative-PCR; RT-PCR, reverse transcriptase-polymerase
chain reaction; rTP, thromboxane receptor.
*COX-2 primers used for Q-PCR.
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Primary antibodies were diluted in tris-buffered saline Tween 20 as
described in Table 2 and incubated with tissue sections at 4o C for
16 h and signals were detected with horseradish peroxidase-
conjugated secondary antibodies (DAKO, anti-rabbit (1:2000 in
5% milk-tris-buffered saline Tween 20). For immunofluorescence,
tissue sections incubated with Alexa Fluor 488-coupled goat anti-
rabbit secondary antibody (A11008) at a dilution of 1:500. Slides
were inspected with an Olympus BX51 microscope with an
Olympus DP50 camera. Negative control with omission of primary
antibody was always run in parallel.
PGE2 measurements in the urine after release of obstruction
Urine was collected and PGE2 excretion was measured 24 h after
release of the ureters. A commercial enzyme immunoassay kit
(Amersham Pharmacia Biotech, Little Chalfont, UK) was used to
determine PGE2 concentration in the urine.
Pelvic pressure measurements
Studies were performed in male Munich-Wistar rats weighing
220–250 g. The rats were anesthetized with isoflurane (Abbott
Scandinavia AB), and operated in the supine position placed on a
heating pad to maintain rectal temperature at 37–381C. After a
midline abdominal incision, the left renal capsule was punctured
with a cannula (24 G/19 mm, BD neoflon, Helsingborg, Sweden) at
the intersection between the cephalocaudal and anteroposterior
planes. At this site, the cannula was directed through the renal
parenchyma into the pelvis. The cannula was connected to a
pressure transducer (Capto SP 844, model MLT 844) and a filling
tube through a three-way stop-coach. The transducer was placed at
the level of the kidney. Pressure waves were continuously displayed
and stored in a computer (PowerLab/8 SP, AD Instruments,
Colorado Springs, CO, USA). Correct positioning of the cannula
in the renal pelvis was assured by infusion of isotonic saline with
room temperature Evan’s blue. Visual inspection of Evan’s blue in
the ureter confirmed the position of the cannula and the infusion
pump was turned off again. The renal pelvis and kidney were
examined for puncture or leakage by visual examination of the dye
after placement of the cannula into the pelvis. After a baseline
period of 30 min, the ureter was occluded for 3 h. After 3 h of
occlusion, the obstruction was released and the pelvic pressure was
measured for another 30 min. During the experiment, rats received a
glucose solution (25 mM, infusion rate 40 ml/min) in order to keep
an adequate urine flow rate and prevent dehydration. The
abdominal incision was kept open and the intraperitoneal organs
were separated from the kidney and ureter and periodically coated
with body-warm isotonic saline and covered with plastic wrap to
prevent evaporation. During pressure measurements, the bladder
was kept empty by continuously drainage of the urine.
Rats were allocated into the following two groups:
Group 1: Seven rats were treated with vehicle. In this group,
osmotic minipumps (Alzet, Scanbur, Denmark) with isotonic saline
were surgically implanted subcutaneously 48 h before the experi-
ment.
Group 2: Six rats were treated with parecoxib. In this group,
osmotic minipumps loaded with 5 mg/kg/day with the selective
COX-2 inhibitor parecoxib (‘Dynastat’ for intravenous infusion,
40 mg/ml in isotonic saline, Pfizer Denmark, Ballerup, Denmark)
were implanted subcutaneously 48 h before the experiment.
Administration of 5 mg/kg/day parecoxib was chosen according to
the pharmacological profile of parecoxib demonstrated previously.27
Statistics
Values are presented as means7s.e.m. Statistical comparisons
between experimental groups were made by a standard unpaired
t-test. P-values o0.05 were considered significant.
For analyzing the pelvic pressure waves, the baseline pelvic
pressure was measured as the lowest between two pressure waves.
This was performed for each pressure wave throughout the
experiment.
CONCLUSION
Our data demonstrate that ureteral obstruction in rat and
human is associated with increased expression of COX-2 and
PGES in the ureteric wall as well as PGE2 release. A COX-2-
specific blocker significantly lowered intrapelvic pressure
after obstruction, indicating that COX-2 activity contributes
to increased pelvic pressure during obstruction. At least four
different prostanoid receptors are expressed in the normal
ureter. Future studies should clarify the involvement of
specific prostanoid receptor subtypes during acute ureteral
obstruction. Elucidation of this may have important clinical
implications for the treatment of pain related to pressure
increase caused by this disorder.
Sham Proximal
ureter
Distal
ureter
Figure 8 | Coomassie-stained 12% polyacrylamide minigel. Sam-
ples of membrane fractions were from ureters from sham-operated,
proximal, and distal obstructed parts of the ureters.
Table 2 | Primary antibodies
Antibody Company Cat. No. Application Dilution
Rat COX-2 Cayman Chemical 160126 Immunoblotting and Immunohistochemistry 1:500
Human COX-2 Cayman Chemical 160107 Immunohistochemistry 1:50
COX-1 Cayman Chemical 160109 Immunoblotting 1:500
COX-1 Santa Cruz SC-1752 Immunohistochemistry 1:50
PGES Cayman Chemical 160140 Immunoblotting and Immunohistochemistry 1:100
EP2 receptor Cayman Chemical 101750 Immunoblotting and Immunohistochemistry 1:100
TP receptor Cayman Chemical 101882 Immunoblotting and Immunohistochemistry 1:100
b-Actin Sigma 3597–100 Immunoblotting 1:1000
COX, cyclooxygenase; EP, prostaglandin E2; PGES, prostaglandin E2 synthase; TP, thromboxane.
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